Elevated levels of plasma von Willebrand factor and the risk of macro- and microvascular disease in type 2 diabetic patients with microalbuminuria

被引:13
|
作者
Gæde, P [1 ]
Vedel, P [1 ]
Parving, HH [1 ]
Pedersen, O [1 ]
机构
[1] Steno Diabet Ctr, DK-2820 Gentofte, Denmark
关键词
cardiovascular disease; endothelial dysfunction; microalbuminuria; microvascular complications; type 2 diabetes mellitus; von Willebrand factor;
D O I
10.1093/ndt/16.10.2028
中图分类号
R3 [基础医学]; R4 [临床医学];
学科分类号
1001 ; 1002 ; 100602 ;
摘要
Background. The purpose of this study was to examine the concept suggesting that microalbuminuria in combination with high levels of plasma von Willebrand factor is a stronger predictor for cardiovascular disease and microvascular complications than microalbuminuria alone in type 2 diabetic patients. Methods. One hundred and sixty patients with type 2 diabetes mellitus and persistent microalbuminuria were followed for an average of 3.8 (SD 0.3) years. 70%, of the patients were treated with angiotensin converting enzyme (ACE)-inhibitors. Patients in this subanalysis were divided into two groups according to baseline plasma von Willebrand factor levels below or above the median. The main outcome was cardiovascular disease (cardiovascular mortality. non-fatal stroke. non-fatal myocardial infarction. coronary artery bypass graft and revascularization or amputation of legs), progression to diabetic nephropathy or progression in diabetic retinopathy. Results. At baseline the two groups were comparable for HbA(jc) fasting levels of s-total-cholesterol, s-HDL-cholesterol and s-triglycerides. systolic and diastolic blood pressure, gender, known diabetes duration, smoking habits. previous cardiovascular disease and antihypertensive therapy as well as retinopathy. Odds ratio for cardiovascular disease was 1.11 (95% CI 0.45-2.73, P = 0.82) (multiple logistic regression), odds ratio for progression to nephropathy was 1.08 (0.41 2.85, P = 0.87) and odds ratio for progression in retinopathy was 0.96 (0.46-2.00, P = 0.92), all with plasma von Willebrand factor levels above the median. Conclusions. Our results do not support the suggestion that the combination of high plasma levels of von Willebrand factor and microalbuminuria is a stronger predictor for cardiovascular disease. progression to diabetic nephropathy or progression in diabetic retinopathy than microalbuminuria alone in patients with type 2 diabetes and persistent microalbuminuria.
引用
收藏
页码:2028 / 2033
页数:6
相关论文
共 50 条
  • [21] Increased plasma levels of endothelin 1 and von Willebrand factor in patients with type 2 diabetes and dyslipidemia
    Seligman, BGS
    Biolo, A
    Polanczyk, CA
    Gross, JL
    Clausell, N
    DIABETES CARE, 2000, 23 (09) : 1395 - 1400
  • [22] Elevated Plasma Von Willebrand Factor and Propeptide Levels in Malawian Children with Malaria
    Phiri, Happy T.
    Bridges, Daniel J.
    Glover, Simon J.
    van Mourik, Jan A.
    de Laat, Bas
    M'baya, Bridon
    Taylor, Terrie E.
    Seydel, Karl B.
    Molyneux, Malcolm E.
    Faragher, E. Brian
    Craig, Alister G.
    Bunn, James E. G.
    PLOS ONE, 2011, 6 (11):
  • [23] von Willebrand factor plasma levels in patients with essential thrombocythaemia
    Bykowska, K.
    Czajkowska, E.
    Letowska, M.
    Sokolowska, B.
    Warzocha, K.
    Odnoczko, E.
    Windyga, J.
    JOURNAL OF THROMBOSIS AND HAEMOSTASIS, 2011, 9 : 197 - 197
  • [24] The anti-von Willebrand factor aptamer ARC1779 increases von Willebrand factor levels and platelet counts in patients with type 2B von Willebrand disease
    Jilma-Stohlawetz, Petra
    Knoebl, Paul
    Gilbert, James C.
    Jilma, Bernd
    THROMBOSIS AND HAEMOSTASIS, 2012, 108 (02) : 284 - 290
  • [25] Relevance of Chloride Binding to Von Willebrand Factor in Type 2B Von Willebrand Disease Patients
    Baronciani, Luciano
    Peyvandi, Flora
    Punzo, Margherita
    Canciani, Maria T.
    Di Stasio, Enrico
    Federici, Augusto B.
    Mannucci, Pier M.
    De Cristofaro, Raimondo
    BLOOD, 2008, 112 (11) : 1161 - 1161
  • [26] Relevance of chloride binding to von Willebrand factor in type 2B von Willebrand disease patients
    Baronciani, L.
    Peyvandi, F.
    Punzo, M.
    Lancellotti, S.
    Canciani, M. T.
    Federici, A. B.
    De Cristofaro, R.
    JOURNAL OF THROMBOSIS AND HAEMOSTASIS, 2010, 8 (02) : 416 - 418
  • [27] The contribution of a reduced von Willebrand factor survival in type 2 von Willebrand disease
    Gallinaro, L.
    Cattini, M. G.
    Pontara, E.
    Sartorello, F.
    Daidone, V
    Padrini, R.
    Bertomoro, A.
    Pagnan, A.
    Casonato, A.
    JOURNAL OF THROMBOSIS AND HAEMOSTASIS, 2009, 7 : 843 - 843
  • [28] Genetic regulation of plasma von Willebrand factor levels in health and disease
    Swystun, L. L.
    Lillicrap, D.
    JOURNAL OF THROMBOSIS AND HAEMOSTASIS, 2018, 16 (12) : 2375 - 2390
  • [29] Plasma levels of von Willebrand factor, von Willebrand factor propeptide and factor VIII in carriers and patients with nephrogenic diabetes insipidus
    Nossent, A. Yael
    Ellenbroek, Johanne H.
    Frolich, Marijke
    Bertina, Rogier M.
    Knoers, Nine V. A. M.
    Eikenboom, Jeroen C. J.
    THROMBOSIS RESEARCH, 2010, 125 (06) : 554 - 556
  • [30] Interaction of factor VIII and von Willebrand factor and the identification of type 2 N von Willebrand disease
    Favaloro, Emmanuel J.
    THROMBOSIS RESEARCH, 2011, 127 (01) : 2 - 3